Model averaging for robust assessment of QT prolongation by concentration‐response analysis
Dosne, A.G., Bergstrand, M., Karlsson, M.O., Renard, D., Heimann, G.
Published in Statistics in medicine (30.10.2017)
Published in Statistics in medicine (30.10.2017)
Get full text
Journal Article
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
Tosca, E. M., Terranova, N., Stuyckens, K., Dosne, A. G., Perera, T., Vialard, J., King, P., Verhulst, T., Perez-Ruixo, J. J., Magni, P., Poggesi, I.
Published in Cancer chemotherapy and pharmacology (2022)
Published in Cancer chemotherapy and pharmacology (2022)
Get full text
Journal Article
932P - Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S., Siefker-Radtke, A., Dosne, A.-G., Zhong, B., Qi, K., Shalaby, W., O’Hagan, A., De Porre, P., Mahadevia, P., Loriot, Y.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
932PHyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S, Siefker-Radtke, A, Dosne, A -G, Zhong, B, Qi, K, Shalaby, W, O’Hagan, A, De Porre, P, Mahadevia, P, Loriot, Y
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Hyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC)
Tagawa, S., Siefker-Radtke, A., Dosne, A.-G., Zhong, B., Qi, K., Shalaby, W., O’Hagan, A., De Porre, P., Mahadevia, P., Loriot, Y.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article